IP78-23: Balancing Benefit and Harm – A Multi-Institutional Evaluation of Toxicity and Efficacy of Adjuvant Pembrolizumab for Patients with High-Risk Clear Cell Renal Cell Carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
147B
Abstract
Information
Other
Best Poster